Dermatology 2026

One of the most common chronic inflammatory skin conditions in the world, acne vulgaris affects people of all races and ethnicities and peaks in adolescence and early adulthood. Follicular hyperkeratinization, androgen-mediated sebum overproduction, Cutibacterium acnes proliferation, immunological and inflammatory responses, and changes in the skin microbiota are all part of the multifactorial pathogenesis that causes the illness. More efficient and focused treatment strategies are required due to the rising incidence of antibiotic resistance, frequent relapse after stopping treatment, and the significant psychological impact of acne. With an emphasis on cutting-edge pharmacological agents, creative drug delivery methods, and tactics intended to increase efficacy while reducing side effects and antibiotic resistance, this study sought to provide a thorough evidence-based review of recent advancements in the treatment of acne vulgaris. Academic textbooks and internet databases, such as PubMed, NCBI, Scopus, Journal of Drugs in Dermatology (JDD), and Google Scholar, were used to conduct a comprehensive literature review. Randomized controlled trials, systematic reviews, meta-analyses, and clinical guidelines were analyzed in publications from 2016 to 2026. According to available data, oral isotretinoin continues to offer the best long-term remission rates for severe acne, while combination topical therapy comprising retinoids, benzoyl peroxide, and topical antibiotics is still the recommended treatment for mild-to-moderate acne. Probiotics, metformin, topical minocycline formulations, clascoterone 1% cream, trifarotene, microneedle-based delivery systems, and device-based modalities are examples of emerging treatments that have shown encouraging clinical results and enhanced safety profiles. In general, targeted, mechanism-based, and microbiome-conscious therapies are becoming more popular in modern acne therapy; however, more high-quality long-term research are needed to determine their relative efficacy and enhance customized treatment plans.

Ahamed Zahid is a final-year MBBS student at Nicolae Testemițanu State University of Medicine and Pharmacy, Chișinău, Republic of Moldova. He is a Research enthusiast whose undergraduate thesis on the “Latest Developments in Acne Treatment” in Dermatology was selected and published as a poster presentation at the BIMCO Conference 2026, a SURGhub Ambassador, and an active member of The Operation Room Global. His clinical interests include surgery, emergency care, dermatology and gastroenterology. Alongside his medical degree, he is gaining hands-on experience and developing skills in dental surgery and implantology through active clinical assistance. Beyond his academic and clinical training, he is actively engaged in medical content creation, academic collaboration, and educational speaking engagements, contributing to knowledge sharing within the healthcare and student communities. He is also engaged in ongoing research in cardiology and endocrinology.